Participant Experiences of Low-Dose Empagliflozin Use as Adjunct Therapy to Hybrid Closed Loop: Findings From a Randomized Controlled Trial
Authors' conclusion
Many participants had positive experiences with low-dose empagliflozin as an adjunct to the hybrid closed-loop therapy. A dedicated study with unblinding would be beneficial to better characterize patient-reported outcomes.
Study context
- Population
- Adults with T1D who completed a crossover RCT of low-dose empagliflozin as adjunct to HCLinterviewed
- Participants
- 24 adults
- Comparison
- Low-dose empagliflozin as adjunct to HCL
Methodological detailssemi-structured interviews, double-blinded, crossover, descriptive analysis
- Semi-structured interviews
- Double-blinded
- Crossover
- Descriptive analysis
Primary result
As reported in the abstract
Participant experiences of low-dose empagliflozin adjunct to HCL
Perceived differences between interventions despite blinding, due to glycemic control or side effects
15
63%
Interested in using low-dose empagliflozin beyond the study
13
54%
Original publication
Participant Experiences of Low-Dose Empagliflozin Use as Adjunct Therapy to Hybrid Closed Loop: Findings From a Randomized Controlled Trial. J Diabetes Sci Technol. Published 25 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →